Skip to main content

Table 3 White blood cell counts and differentials

From: Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

   Cell Count per mm3 of Blood (mean ± SD)
   Total WBCs Lymphocyte Monocyte Eosinophil
Thalidomide      
HIV+ pre 6765 ± 2286 1700 ± 927 359 ± 276 318 ± 247
  mid 6403 ± 2489 1438 ± 669 320 ± 237 463 ± 562
  post 6331 ± 1564 1784 ± 1165 427 ± 273 703 ± 562
HIV pre 8435 ± 3519 1762 ± 876 579 ± 367 513 ± 492
  mid 7560 ± 2402 2402 ± 1294 393 ± 301 524 ± 613
  post 6941 ± 1735 2310 ± 801 454 ± 393 445 ± 451
Placebo      
HIV+/1 pre 7573 ± 3289 1699 ± 440 616 ± 392 195 ± 151
  mid 6806 ± 3035 2140 ± 1019 336 ± 198 317 ± 321
  post 6588 ± 4012 2024 ± 806 282 ± 170 178 ± 167
  1. Results are means ± one standard deviation (SD) evaluated before (pre), during (mid), and 5 days after (post) 14-day treatment cycles with 300 mg/day of thalidomide or placebo (see Table 1). No significant changes were observed. WBC, white blood cells.